CAS 1201902-80-8

MLN9708

Description:

MLN9708, also known as ixazomib, is a small molecule proteasome inhibitor primarily used in the treatment of multiple myeloma. It functions by disrupting the proteasome's ability to degrade ubiquitinated proteins, leading to the accumulation of pro-apoptotic factors and ultimately inducing cancer cell death. This compound is characterized by its oral bioavailability, which distinguishes it from many other proteasome inhibitors that require intravenous administration. MLN9708 exhibits a favorable pharmacokinetic profile, allowing for once-weekly dosing in clinical settings. Its mechanism of action not only targets malignant cells but also has implications for modulating the tumor microenvironment. Additionally, MLN9708 has been studied in combination with other therapies, enhancing its efficacy and providing a synergistic effect in treating resistant forms of multiple myeloma. As a relatively novel therapeutic agent, ongoing research continues to explore its potential applications and effectiveness in various hematological malignancies and solid tumors.

Formula: C₂₀H₂₃BCl₂N₂O₉

Synonyms:

• 4-Carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid
• Ixazomib

1,3,2-Dioxaborinane-4-acetic acid, 4-carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-

CAS: 1201902-80-8

Formula: C₂₀H₂₃BCl₂N₂O₉

Purity: 98%

Color and Shape: Solid

Molecular weight: 517.1216

Ref: IN-DA000QJT

4-(Carboxymethyl)-2-((R)-1-(2-(2,5-Dichlorobenzamido)Acetamido)-3-Methylbutyl)-6-Oxo-1,3,2-Dioxaborinane-4-Carboxylic Acid

CAS: 1201902-80-8

4-(Carboxymethyl)-2-((R)-1-(2-(2,5-Dichlorobenzamido)Acetamido)-3-Methylbutyl)-6-Oxo-1,3,2-Dioxaborinane-4-Carboxylic Acid

Purity: 99%

Molecular weight: 517.12g/mol

Ref: 54-OR1025575

MLN9708

CAS: 1201902-80-8

MLN9708

Purity: ≥95%

Molecular weight: 517.12g/mol

Ref: 54-BUP13453

MLN9708 analogues

CAS: 1201902-80-8

MLN2238 inhibits 20S proteasome's β5 site (Ki50=0.93 nM, IC50=3.4 nM), active form of Ixazomib Citrate in solutions/plasma.

Formula: C₂₀H₂₃BCl₂N₂O₉

Purity: 98.24% - 99.23%

Color and Shape: Solid

Molecular weight: 517.12

Ref: TM-T2016

Ixazomib Citrate

Controlled Product

CAS: 1201902-80-8

Formula: C₂₀H₂₃BCl₂N₂O₉

Color and Shape: Neat

Molecular weight: 517.12

Ref: TR-I216035

MLN-9708

Controlled Product

CAS: 1201902-80-8

Applications MLN-9708 is a novel proteasome inhibitor.
References Kupperman, Erik., et al.: Cancer Res., 70, 1970 (2010);

Formula: C₂₀H₂₃BCl₂N₂O₉

Color and Shape: Neat

Molecular weight: 517.12

Ref: TR-M425158

Ixazomib Citrate (MLN9708)

CAS: 1201902-80-8

Ixazomib Citrate (MLN9708) is a proteasome inhibitor that belongs to the class of investigational agents. It has minimal toxicity and is being investigated for use in the treatment of multiple myeloma, a type of cancer that starts in the bone marrow. Ixazomib Citrate inhibits the activity of proteasomes, which are cellular structures responsible for degrading proteins. This inhibition leads to an increase in the number of cells with damaged DNA and an increase in apoptosis. Ixazomib Citrate synergizes with other chemotherapeutic agents, such as bortezomib, to promote apoptosis by activating caspases and decreasing cell proliferation. The biochemical properties of this drug include its ability to inhibit protein synthesis by inhibiting eukaryotic ribosomes and its ability to bind to DNA at specific sites.

Formula: C₂₀H₂₃BCl₂N₂O₉

Purity: Min. 95%

Molecular weight: 517.12 g/mol

Ref: 3D-BYB90280